Contraria Biotech
Develops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics.
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 127 % | 507 % | (21 %) | (77 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (302 %) | (354 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (493 %) | (523 %) | (45 %) | (59 %) | (600 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Achilles Vaccines operates in the biopharmaceutical sector, focusing on the early-stage development of vaccines and immunotherapeutics. The company leverages a versatile technology platform that utilizes bacteria to produce self-adjuvanting vesicles capable of delivering antigenic molecules. Achilles Vaccines serves clients in the healthcare and pharmaceutical industries, addressing critical needs such as malaria, COVID-19, and bacterial infections. The company employs advanced laboratory and digital technologies, including the NGVR method, to rapidly identify effective vaccine targets. Its business model revolves around research and development, supported by significant seed financing and partnerships, such as the EU Malaria Fund. Revenue is generated through the development and commercialization of biopharmaceutical products, including vaccines and immunotherapeutics.
Keywords: biopharmaceutical, vaccines, immunotherapeutics, NGVR, bacterial infections, malaria, COVID-19, biotechnology, advanced technology, early-stage development.